ScreenerHero

ONCOZ OncoZenge AB (publ)

STO · SE · Healthcare · Biotechnology · oncozenge.com
3.315SEK+0.30%Mkt Cap: 7.94M $P/E: —

OncoZenge AB (publ), is a clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Swe…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap7.94M USD
Enterprise Value5.09M USD
Revenue (TTM)571.33K USD
Gross Profit571.33K USD
Net Income (TTM)-1.52M USD
Revenue/Share0.46 SEK
Last Price3.315 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0015504097
Valuation
P/E (Trailing)—
P/E (Forward)-16.52
PEG—
EV/EBITDA—
EV/Revenue8.90
P/S13.86
P/B4.73
EPS (TTM)-1.67
EPS (Forward)-0.20
52W Range
3.1003% of range10.28
52W High10.28 SEK
52W Low3.100 SEK
Profitability
Gross Margin100.00%
Oper. Margin-91.25%
EBITDA Margin0.00%
Profit Margin-598.35%
ROE-188.04%
ROA-65.33%
Growth
Revenue Growth4996.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.25M USD
CapEx (TTM)—
FCF Margin-210.73%
FCF Yield-15.16%
Net Debt645.75K USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.88
Current Ratio0.51
Quick Ratio0.35
Book Value/Sh0.70 SEK
Cash/Share0.05 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 SEK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.000 SEK
Upside (mean)+141.3%
Target Range8.000 SEK – 8.000 SEK
# Analysts1
Ownership
Shares Out.25.05M
Float5.54M
Insiders31.08%
Institutions8.72%
Technical
SMA 504.654 (-28.8%)
SMA 2005.878 (-43.6%)
Beta1.35
S&P 52W Chg16.45%
Avg Vol (30d)63.32K
Avg Vol (10d)58.96K
Technical Indicators
RSI (14)37.1
MACD-0.3388
MACD Signal-0.4354
MACD Hist.+0.0966
BB Upper3.599 SEK
BB Middle3.374 SEK
BB Lower3.149 SEK
BB Width13.34%
ATR (14)0.3648 SEK
Vol Ratio (20d)0.56x